IMTX Jan 2025 10.000 put
| Previous close | 1.9600 |
| Open | 1.9600 |
| Bid | 0.0000 |
| Ask | 4.0000 |
| Strike | 10.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.9600 - 1.9600 |
| Contract range | N/A |
| Volume | |
| Open interest | 130 |
Globe NewswireImmatics Announces First Quarter 2024 Financial Results and Business Update
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor shrinkage achieved in 87% of patients; median duration of response of 13.5 months including 11/16 ongoing confirmed responses; IMA203 continues to maintain a favorable safety profileRegistration-enabling
- Globe Newswire
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well toleratedRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 GEN1 in 2L+ melanoma planned to begin in 2024 Next data update on IMA203 GEN1 and IMA203CD8 GEN2 planned for 2H 2024 First clinical data updates for Immatics’ next-generation TCR Bispe
Simply Wall St.With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
Key Insights Institutions' substantial holdings in Immatics implies that they have significant influence over the...
